StockData

Ionis Pharmaceuticals vs Pacira BioSciences

IONS and PCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How IONS and PCRX compare

Ionis Pharmaceuticals is the larger company, worth 3.1 times as much as Pacira BioSciences ($4.5B against $1.5B).

Pacira BioSciences grew revenue faster over the last twelve months (5.7% versus −7.4% for Ionis Pharmaceuticals).

Pacira BioSciences keeps more of each dollar of sales as profit, with a net margin of 2.0% compared with −64.7% at Ionis Pharmaceuticals.

Pacira BioSciences scores higher on the StockData Score (6 against 4 for Ionis Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricIONSPCRX
Size and price
Market cap$4.5B$1.5B
Share price$26.96$36.48
Change, 1 year−62.3%53.4%
Change, 5 years−7.2%−29.3%
Beta (5Y)0.600.12
Employees1,402829
StockData Score
Total score46 (better)
Valuation score1 (better)0
Growth score2 (better)1
Performance score03 (better)
Health score12 (better)
Dividend score00
Valuation
P/E–104×
P/S5.1×1.9× (better)
P/B10.2×2.2× (better)
EV/EBITDA–14.9×
P/FCF–8.1×
FCF yield−12.5%12.3% (better)
Fair value$27.86$28.47
Margin of safety3.2% (better)−28.1%
Growth
Revenue growth (TTM)−7.4%5.7% (better)
Revenue growth, 5Y average5.3%11.1% (better)
EPS growth, 5Y average–−45.5%
Profitability
Gross margin98.2% (better)79.2%
Operating margin−68.0%2.7% (better)
Net margin−64.7%2.0% (better)
FCF margin−64.2%24.1% (better)
Return on equity−105%2.0% (better)
Return on invested capital–3.0%
Financial health
Debt / equity–0.54
Net debt / EBITDA–1.07
Interest coverage−31.6×1.3× (better)
Current ratio7.89 (better)5.04
Altman Z-score0.232.44 (better)
Piotroski F-score48 (better)
Dividends and buybacks
Buyback yield–10.2%
Shareholder yield0.00%10.2% (better)
Ownership
Held by institutions108%110%
Held by insiders0.81%6.1%
Insider net buying, 12 months−$114M−$2.4M (better)
Superinvestors holding1–
Short interest, % of float12.8%8.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.